Pancreatic Cancer Radiation Therapy Gets New Guidelines

This episode looks at ASTRO's 2026 update to its pancreatic cancer radiation guideline, the American Society for Radiation Oncology's first revision since 2019. We break down what changed, what the evidence shows, and what still needs to be proven.

You'll learn:
- Why ASTRO updated its pancreatic cancer radiation guideline for the first time since 2019
- How the new guideline supports dose escalation with stereotactic body radiation therapy
- Why online adaptive radiation planning is now recommended whenever that dose is escalated
- What the PREOPANC-2, CONKO-007, and SABER trials found about local tumor control and survival
- Why the ongoing NRG-GI011 trial matters for proving a survival benefit
- How access to advanced adaptive treatment technology still varies by hospital
- What the update means for a newly diagnosed pancreatic cancer patient

The takeaway is that radiation technique keeps improving, but the survival question is still being tested in ongoing trials. For the full details and sourcing, read the article linked below.

Blog Link: New 2026 Pancreatic Cancer Radiation Guidelines: What Patients Should Know

Send us Fan Mail

Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.

Author: Dr. CHRISTINA NG VAN TZE

📍 Visit us at oncolifecentre.com
📞 Call: +60 3 2242 3260
📧 Book a consultation or ask a question — we're here to support your journey.